Valuation: Assembly Biosciences, Inc.

Market Cap 569M 498M 459M 425M 807M 54.35B 820M 5.5B 2.16B 26.69B 2.14B 2.09B 92.44B P/E 2026 *
-26.5x
P/E 2027 * -10x
Enterprise Value 569M 498M 459M 425M 807M 54.35B 820M 5.5B 2.16B 26.69B 2.14B 2.09B 92.44B EV / Sales 2026 *
12.5x
EV / Sales 2027 * 17.7x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-2.99%
1 week+0.47%
Current month+1.42%
1 month+22.67%
3 months-6.63%
6 months-12.19%
Current year-18.05%
1 week 27.2
Extreme 27.2
29.94
1 month 21.8
Extreme 21.795
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Director

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%+0.47%+48.88%+117.06% 569M
+1.68%+3.55%+4.86%+10.97% 49.42B
+0.72%+1.00%+396.18%+602.43% 40.34B
+2.54%+0.93%+28.98%-4.77% 34.01B
+0.31%+1.74%+18.44%+57.29% 33.56B
-2.09%-0.80%+3.56%+33.56% 26.84B
-0.63%+0.34% - - 17.22B
+0.66%-3.96%+66.85%+121.47% 15.19B
-23.90%-21.43%+50.06%+53.83% 13.96B
+2.59%+0.50%+15.28%+21.25% 13.36B
Average -2.12%+1.29%+70.34%+112.57% 24.45B
Weighted average by Cap. -0.63%+0.91%+87.43%+134.01%

Financials

2026 *2027 *
Net sales 45.47M 39.78M 36.68M 33.94M 64.42M 4.34B 65.5M 439M 172M 2.13B 171M 167M 7.38B 32.25M 28.21M 26.02M 24.07M 45.69M 3.08B 46.45M 312M 122M 1.51B 121M 118M 5.24B
Net income -20.46M -17.9M -16.51M -15.27M -28.99M -1.95B -29.47M -198M -77.5M -959M -76.82M -75.16M -3.32B -56.38M -49.32M -45.48M -42.08M -79.87M -5.38B -81.21M -545M -214M -2.64B -212M -207M -9.15B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
10/07/26 $27.87 -2.99% 179,037
08/07/26 $28.73 -0.81% 135,958
07/07/26 $28.97 +0.24% 177,789
06/07/26 $28.90 +4.16% 179,400
02/07/26 $27.74 +3.93% 199,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
28.73USD
Average target price
50.00USD
Spread / Average Target
+74.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock